Evidence-informed pharmacology monograph, updated 10 November 2026. For medical education; individual management requires current product labeling and qualified clinical assessment.
Overview and chemistry
Isosorbide dinitrate (ISDN) is an organic nitrate ester used for prevention of angina and, in combination with hydralazine, selected heart-failure indications. Its correct molecular formula is C6H8N2O8, not C6H10O8. Oral immediate-release ISDN is not a preferred emergency agent to abort an acute angina episode because onset is insufficiently rapid [1,2].
Pharmacodynamic mechanism
ISDN undergoes enzymatic biotransformation to produce bioactive nitric oxide-related signaling molecules. Activation of soluble guanylyl cyclase increases intracellular cyclic GMP, promoting vascular smooth-muscle relaxation. At typical doses venodilation predominates, lowering cardiac preload and myocardial oxygen demand; arterial and coronary dilation may also occur. This is symptom-relieving hemodynamic therapy, not a direct antiplatelet or thrombolytic drug [1].
Therapeutic applications
Oral ISDN can prevent episodes of chronic stable angina when appropriately scheduled, whereas sublingual nitroglycerin is commonly used for rapid relief. The 2022 AHA/ACC/HFSA guideline recommends hydralazine plus ISDN to improve outcomes in self-identified African American patients with NYHA class III–IV HFrEF despite optimal treatment; the combination may be considered for selected patients unable to take first-line renin–angiotensin system therapies. The evidence should not be generalized to HFpEF or ISDN monotherapy as established survival treatment [2].
Pharmacokinetics and nitrate tolerance
Oral ISDN undergoes extensive first-pass metabolism to active isosorbide mononitrate metabolites. Continuous nitrate exposure can produce tolerance and diminish antianginal activity; short-acting divided dosing often incorporates a sufficiently long daily nitrate-low interval according to the product and regimen. Abrupt changes can provoke rebound angina in susceptible patients; avoid empirical regimen alterations [1].
Contraindicated interactions
Combining ISDN with phosphodiesterase-5 inhibitors such as sildenafil, tadalafil or vardenafil can produce severe hypotension, syncope or ischemia; combining it with soluble guanylyl cyclase stimulators such as riociguat is also contraindicated. The precise time between exposure to PDE5 inhibitors and nitrates is agent- and situation-specific; screen carefully. Alcohol, antihypertensives and other vasodilators may add to hypotensive effects [1].
Adverse effects and clinical precautions
Headache, flushing, orthostatic dizziness, hypotension and reflex tachycardia are common. Volume depletion, shock and suspected right ventricular infarction warrant special caution because of preload dependence. Teach patients which preparation is for ongoing prophylaxis versus rapid relief and when chest pain requires emergency assessment. In HFrEF, ISDN–hydralazine is an adjunct to other indicated mortality-reducing medicines, not a substitute for them [1,2].
References
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- DailyMed. Isosorbide dinitrate oral tablets: US prescribing information, updated July 31, 2026. Available from: https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?audience=professional&setid=6df6a2fa-c56c-4eb6-a485-c16585420eb0
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for management of heart failure. Circulation. 2022;145:e895–e1032. Available from: https://www.jacc.org/doi/10.1016/j.jacc.2021.12.012
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.